AUS
NZ
UK
CA
USA
IND
Highlights
- SDI Limited's scheme of arrangement has become effective following Supreme Court approval and ASIC lodgement.
- Trading in SDI shares has been suspended from the close of trading as the acquisition moves towards completion.
- The transaction marks another significant corporate development within the ASX Healthcare Stocks sector as the ASX 300 continues to see merger and acquisition activity.
SDI's acquisition has reached a major milestone after its scheme of arrangement became effective. Trading has been suspended as the healthcare company moves towards completing its acquisition.
Australian healthcare stocks continue to attract corporate interest, with SDI Limited (ASX:SDI) reaching a major milestone in its proposed acquisition. The dental materials manufacturer has confirmed that its scheme of arrangement is now effective after receiving the necessary court approval and completing regulatory lodgement requirements. The development signals another notable transaction within the ASX Healthcare Stocks category and highlights the continued role of merger activity across the ASX 300 .
Scheme Of Arrangement Officially Takes Effect
SDI announced that its proposed scheme of arrangement has officially become effective following the lodgement of the Supreme Court of New South Wales orders with the Australian Securities and Investments Commission.
The transaction will see InnoXvest Dental Pty. Ltd., a wholly owned subsidiary of Beijing Guoci Kebo Technology Co., Ltd., acquire all issued shares in SDI through an all-cash transaction.
Completion of this regulatory step confirms that the acquisition has progressed beyond shareholder and court approval, allowing the implementation process to move forward.
The company noted that the transaction remains subject to the remaining implementation timetable.
ASX Trading Suspension Begins
Following the scheme becoming effective, quotation of SDI shares on the Australian Securities Exchange has been suspended from the close of trading.
Trading suspensions are a standard part of scheme implementation once the legal process reaches the effective stage. The suspension ensures orderly completion of the acquisition before shareholders receive the agreed cash consideration.
With trading now halted, shareholders will no longer be able to buy or sell SDI shares on the ASX while the transaction proceeds towards completion.
Cash Acquisition Moves Closer
Under the approved scheme, eligible shareholders will receive cash consideration for every SDI share held on the record date.
The implementation of the acquisition is expected to occur in early July, subject to completion of the remaining procedural requirements outlined in the scheme timetable.
The record date will determine which shareholders are entitled to participate in the scheme consideration.
SDI also noted that any changes to the implementation schedule would be communicated through future ASX announcements.
Who Is Acquiring SDI?
The acquiring entity is InnoXvest Dental Pty. Ltd., which is wholly owned by Beijing Guoci Kebo Technology Co., Ltd.
Beijing Guoci Kebo Technology is controlled by Shenzhen Stock Exchange-listed Shandong Sinocera Functional Material Co. Ltd., extending the transaction into the broader international healthcare and advanced materials sector.
The acquisition represents another example of overseas interest in established Australian healthcare manufacturers with specialised product portfolios.
SDI's Position In The Dental Market
SDI has built its reputation as an Australian manufacturer and global supplier of specialist dental materials.
Its portfolio includes restorative dental products such as dental composites, adhesives, cements, amalgams and professional tooth-whitening systems supplied to international markets.
The company's specialised manufacturing capability has helped establish its presence across numerous global dental markets, making it a recognised participant within Australia's healthcare manufacturing industry.
Why Healthcare M&A Activity Remains Active
Healthcare continues to attract merger and acquisition activity because many companies operate in specialised markets supported by proprietary products, intellectual property and established customer relationships.
Businesses with proven manufacturing capabilities, global distribution networks and niche healthcare expertise often become attractive acquisition targets for larger international groups seeking expansion opportunities.
The latest SDI transaction reflects this broader trend, where strategic buyers continue to identify opportunities within Australian healthcare businesses.
Regulatory Milestone Brings Greater Certainty
Court approval and ASIC lodgement represent two of the most significant legal milestones in a scheme of arrangement.
Once these requirements are completed, the scheme becomes effective and the transaction moves into its final implementation phase.
This provides greater certainty regarding the completion process while allowing shareholders to prepare for the final settlement under the approved timetable.
What Happens Next?
The remaining focus now shifts towards implementation.
Eligible shareholders recorded on the register at the specified record date will receive the agreed cash consideration once the implementation date arrives.
Following completion, SDI will cease to be listed on the Australian Securities Exchange, concluding its journey as an ASX-listed company.
What This Means For The Healthcare Sector
The transaction highlights continuing corporate activity across Australian healthcare companies despite broader market uncertainty.
Strategic acquisitions remain an important feature of the healthcare industry as international groups continue seeking established businesses with specialised products and global customer relationships.
For the broader market, the transaction demonstrates that corporate activity continues to play a meaningful role alongside regular earnings updates and operational announcements.
SDI has reached a defining milestone after its scheme of arrangement officially became effective. With court approval secured, ASIC lodgement completed and trading now suspended, the acquisition is progressing towards final implementation.
The transaction reflects continued merger activity across Australia's healthcare sector and demonstrates ongoing international interest in specialised Australian healthcare manufacturers. As implementation proceeds, eligible shareholders are expected to receive the agreed cash consideration under the approved scheme timetable.
